THERAVANCE INC - CORPORATE OBLIG

CUSIP: 88338TAB0

Q4 2018 13F Holders as of 31 Dec 2018

Type / Class
Debt / CORPORATE OBLIG
Market price (% of par)
108.0%
Total 13F principal
$227,474,261
Principal change
-$16,008,745
Total reported market value
$245,819,008
Number of holders
27
Value change
-$15,927,276
Number of buys
9
Number of sells
16

Quarterly Holders Quick Answers

What is CUSIP 88338TAB0?
CUSIP 88338TAB0 identifies 88338TAB0 - THERAVANCE INC - CORPORATE OBLIG in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of THERAVANCE INC - CORPORATE OBLIG as of Q4 2018

As of 31 Dec 2018, THERAVANCE INC - CORPORATE OBLIG was held by 27 institutional bondholders reporting positions in Form 13F filings. These institutions reported holding $227,474,261 in principal (par value) of the bond. The largest 10 bondholders included Linden Advisors LP, ADVENT CAPITAL MANAGEMENT /DE/, Antara Capital LP, CNH PARTNERS LLC, OAKTREE CAPITAL MANAGEMENT LP, CALAMOS ADVISORS LLC, LAZARD ASSET MANAGEMENT LLC, SSI INVESTMENT MANAGEMENT INC, Jefferies Group LLC, and BANK OF AMERICA CORP /DE/. This page lists 27 institutional bondholders reporting positions for the Q4 2018 filing period.
Investor Option Weight % Change % Value $ * Price (% of par) Principal Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.